KORU Medical Systems, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 12, 2026, discloses significant executive leadership changes at KORU Medical Systems, Inc. The filing details the retirement of the current Chief Executive Officer and the appointment of a successor, along with the associated compensation and transition agreements.
Key Financial Metrics and Compensation
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it outlines specific compensation figures related to the executive transition:
- Outgoing CEO (Linda Tharby): Will receive a 2025 bonus at 100% payout and a prorated 2026 bonus. During the advisory period (July 1, 2026 – December 31, 2026), she will receive 50% of her base salary. She retains 220,000 vested PSUs from 2025 performance.
- Incoming CEO (Adam Kalbermatten): Annual base salary is set at $450,000 through June 30, 2026, increasing to $525,000 effective July 1, 2026.
- Equity Awards: Mr. Kalbermatten received a 2025 long-term incentive award valued at $550,000. His target 2026 award is valued at $1,250,000. Additionally, he will receive a one-time "Promotion PSU" award valued at $1,250,000 effective July 1, 2026.
Material Changes
The primary material change is the departure of Linda Tharby as President and CEO and the appointment of Adam Kalbermatten to these roles.
- Leadership Transition: Ms. Tharby retires as CEO effective June 30, 2026. Mr. Kalbermatten becomes President effective March 15, 2026, and CEO effective July 1, 2026.
- Board Composition: Ms. Tharby will remain on the Board until December 31, 2026. Mr. Kalbermatten is scheduled to be appointed to the Board effective January 1, 2027.
- Compensation Structure: The filing introduces new employment terms for the incoming CEO, including specific salary tiers and performance-based equity targets tied to revenue growth and market capitalization.
Outlook, Risks, and Contingencies
Management commentary focuses on ensuring an orderly transition. Key contingencies and risks include:
- Performance Conditions: Mr. Kalbermatten's Promotion PSU award is contingent on multi-year performance objectives, weighted 75% on revenue growth and 25% on market capitalization.
- Change of Control: Both agreements contain acceleration provisions for equity awards in the event of a Change of Control. Ms. Tharby waived rights to vesting under trailing revenue run-rate provisions in such an event.
- Restrictive Covenants: Ms. Tharby is subject to non-competition and non-solicitation covenants through the later of the end of the Advisory Period or the extended option exercise window.
Investor Verification Checklist
- Verify the exact vesting schedule and performance metrics for Mr. Kalbermatten's $1,250,000 Promotion PSU award.
- Confirm the total cash and equity compensation cost to the company for Ms. Tharby's transition period through December 31, 2026.
- Review the full text of Exhibits 10.1 and 10.2 for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Monitor the company's revenue growth trajectory, as it constitutes 75% of the new CEO's performance-based equity vesting.